Table 1 Activity of DPPIV in serum, % of CD26+ lymphocytes and % of CD26+ white blood cells, mean fluorescence intensity (MFI) of CD26 expression on lymphocytes and % of lymphocytes in healthy controls, people with vitiligo, patients with melanoma, and in patients with other malignant skin tumors and benign changes of the skin

Healthy controls

40

27.03 ± 7.00

50.33 ± 11.85

11.26 ± 5.26

278.41 ± 138.82

20.65 ± 8.48

Vitiligo

16

29.51 ± 7.24

48.04 ± 10.02

8.41 ± 3.30

690.29 ± 907.96

16.50 ± 4.51

Melanoma

64

21.81 ± 6.79 *

52.93 ± 10.77

7.16 ± 3.63 **

377.21 ± 554.38

13.43 ± 6.13 ***

Melanoma without metastatic disease

27

21.53 ± 6.74

53.24 ± 9.92

6.40 ± 3.28

409.51 ± 686.61

12.18 ± 5.91

Melanoma with metastatic disease

37

22.02 ± 6.91

52.71 ± 11.49

7.71 ± 3.81

353.64 ± 442.73

14.35 ± 6.19

Other malignant skin tumors

6

23.08 ± 8.28

47.17 ± 7.93

7.06 ± 3.28

235.73 ± 172.32

13.36 ± 6.02

Benign skin changes

6

27.32 ± 12.96

54.64 ± 10.78

9.19 ± 4.32

249.45 ± 237.82

15.77 ± 6.17